Soligenix

Soligenix(SNGX)

PRINCETON, NJ
Biotechnology

Focus: Lipoprotein Delivery, Small Molecules

Soligenix is a life sciences company focused on Lipoprotein Delivery, Small Molecules.

OncologyGastroenterologyImmunology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

SGX201
Enteritis
Phase 1/2
Clinical Trials (1)
NCT01073384A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
Phase 1/2
Clinical Trials (1)
NCT05872854Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Phase 2
Hypericin
Psoriasis
Phase 2
Clinical Trials (1)
NCT05442190Topical SGX302 for Mild-to-Moderate Psoriasis
Phase 2
Clinical Trials (1)
NCT05380635PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Phase 2
Phase 2
Clinical Trials (1)
NCT02013050A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
Phase 2
Clinical Trials (1)
NCT01925950Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Phase 2
Clinical Trials (1)
NCT06149247HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Phase 2
Dusquetide
Behçet Disease
Phase 2
Clinical Trials (1)
NCT06386744Dusquetide for the Treatment of Behcet's Disease
Phase 2
Clinical Trials (1)
NCT02448381FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Phase 3
Clinical Trials (1)
NCT03237325DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
Phase 3
oral beclomethasone 17,21-dipropionate
Acute Gastrointestinal Graft vs Host Disease
Phase 3
Clinical Trials (1)
NCT00926575Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
Phase 3
Phase 3
Clinical Trials (1)
NCT06470451Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 12 clinical trials
Top TAs: Oncology, Gastroenterology, Immunology
Publications: 25 in PubMed
SEC Filings: 2 available
Therapeutic Area Focus
Oncology
6 pipeline
Immunology
1 pipeline
Marketed
Pipeline

Financials (FY2024)

Revenue
$839K12%
R&D Spend
$3M(395%)58%
Net Income
-$6M